U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Orange Book Home

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 214522

Marketing Status: Prescription
Active Ingredient: TADALAFIL
Proprietary Name: TADLIQ
Dosage Form; Route of Administration: SUSPENSION; ORAL
Strength: 20MG/5ML
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: 
Application Number: N214522
Product Number: 001
Approval Date: Jun 17, 2022
Applicant Holder Full Name: CMP DEVELOPMENT LLC
Marketing Status:  Prescription
Patent and Exclusivity Information
Back to Top